This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Acadia Pharma FDA Advisory Panel Live Blog

A panel of outside experts selected by the FDA are reviewing a Parkinson's disease drug developed by Acadia Pharmaceuticals.

Acadia's Parkinson's Drug Hit With Critical FDA Review Ahead of Tuesday Panel

The outcome of the panel vote is hugely important to Acadia. An affirmative decision would most likely compel FDA to approve Nuplazid by its decision date of May 1.

Can Biotech Stocks Outperform the Broader Market in 2016?

A small plurality of health care investors believe biotech stocks will outperform the broader market for the balance of 2016, according to a survey conducted in March by JPMorgan.

Gilead, Biogen Troubles Remind Investors Why Strong Drug Patents Are Vital

A flurry of patent infringement lawsuits and decisions are affecting some of the biotech sector's largest companies.

Biotech Stock Mailbag: How to Spot Red Flags in Clinical Trial Data

TheStreet's senior columnist Adam Feuerstein answers reader questions about biotech stocks.

Sarepta Bolstered by Doctor Letter Urging FDA Approval of DMD Drug

36 doctors, all experts in Duchenne muscular dystrophy, have written a letter to the U.S. Food and Drug Administration urging the agency to approve Sarepta Therapeutics' experimental therapy eteplirsen.

BioMarin PKU Drug Shows Mixed Results in Pivotal Study

Based on these study results, BioMarin intends to file pegvaliase for approval with the FDA by the end of the year, 'subject to further discussions' with the agency.

Biotech Stock Mailbag: Sector Blues, Celator, Mannkind, GW Pharma

TheStreet's biotech columnist Adam Feuerstein answers reader questions about biotech stocks.

Gilead Cancer Business Loses Top Exec Prior to Study Halts

Gilead's cancer business, a hoped-for source of future earnings growth, has hit some turbulence.

Amgen Victorious Over Regeneron, Sanofi in Cholesterol Drug Patent Lawsuit

A jury ruled in favor of Amgen in a patent infringement case covering a new class of cholesterol-lowering drugs that the biotech company filed against Regeneron Pharmaceuticals and Sanofi.

Page 4 of 357
Top Rated Stocks Top Rated Funds Top Rated ETFs